U.S., May 21 -- ClinicalTrials.gov registry received information related to the study (NCT06979505) titled 'GV101 in Healthy Obese Participants' on May 13.
Brief Summary: The purpose of this trial is to evaluate the efficacy and safety of GV101 for weight loss over a range of doses in participants with obesity. The primary efficacy endpoint is the mean percent change in body weight from baseline at Week 16 in each treated group as compared with placebo.
Study Start Date: July, 2025
Study Type: INTERVENTIONAL
Condition:
Weight Management
Intervention:
DRUG: GV101
GV101 suspension
DRUG: GV101 placebo
GV101 placebo suspension
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Graviton Bioscience Corporation
Disclaimer: Curated by HT ...